Eli Lilly and Company (NYSE:LLY) has been assigned a $86.00 price target by stock analysts at Morgan Stanley in a research report issued on Friday. The brokerage presently has a “hold” rating on the stock. Morgan Stanley’s target price points to a potential downside of 1.24% from the stock’s current price.
Other research analysts have also issued reports about the company. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Citigroup Inc. restated a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a research note on Tuesday, July 4th. Jefferies Group LLC restated a “buy” rating and issued a $93.00 target price on shares of Eli Lilly and in a research note on Thursday, June 22nd. Deutsche Bank AG restated a “buy” rating and issued a $91.00 target price (up from $90.00) on shares of Eli Lilly and in a research note on Monday, July 17th. Finally, Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research note on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. Eli Lilly and currently has an average rating of “Hold” and a consensus target price of $88.42.
Shares of Eli Lilly and (NYSE:LLY) opened at 87.08 on Friday. The company has a market cap of $91.87 billion, a price-to-earnings ratio of 37.68 and a beta of 0.34. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $89.09. The firm’s 50-day moving average is $82.21 and its 200 day moving average is $82.15.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.86 earnings per share. Equities analysts expect that Eli Lilly and will post $4.16 EPS for the current fiscal year.
WARNING: This report was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://transcriptdaily.com/2017/10/08/eli-lilly-and-company-lly-given-a-86-00-price-target-by-morgan-stanley-analysts.html.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 990,000 shares of company stock valued at $82,949,650. 0.20% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. Joel Isaacson & Co. LLC boosted its holdings in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after acquiring an additional 50 shares during the last quarter. Sumitomo Life Insurance Co. boosted its holdings in Eli Lilly and by 4.4% in the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after acquiring an additional 1,370 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Eli Lilly and by 7.8% in the second quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock valued at $55,258,000 after acquiring an additional 48,706 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after acquiring an additional 1,441,200 shares during the last quarter. Finally, Stephens Inc. AR boosted its holdings in Eli Lilly and by 4.5% in the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after acquiring an additional 1,901 shares during the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.